Neurovance, Inc. Company Profile

08:58 EDT 30th October 2014 | BioPortfolio

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurovance also holds a substantial portfolio of research stage reuptake inhibitors.


News Articles [10 Associated News Articles listed on BioPortfolio]

Neurovance’s Non-Stimulant ADHD Drug Could Challenge Stimulants

Neurovance Inc. announced complete results from its Phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (

Neurovance Completes Enrollment in Abuse Liability Study

Neurovance Inc. announced that it has completed enrollment in a human abuse liability (HAL) study of centanafadine (formerly EB-1020). Centanafadine is a novel non-stimulant being developed for the tr...

Neurovance closes patient enrolment in HAL study for ADHD treatment centanafadine

US-based neuroscience-focused firm Neurovance has completed patient enrolment in a human abuse liability (HAL) study of centanafadine (formerly EB-1020), a new non-stimulant being developed for the tr...

Neurovance completes patient enrollment in HAL study for centanafadine to treat ADHD

Neurovance, a US-based neuroscience-focused company has completed enrollment in a human abuse liability (HAL) study of centanafadine (formerly EB-1020), a new non-stimulant being developed to treat ad...

Neurovance Reports Positive Phase 2 Results For Non-Stimulant ADHD Drug

Neuroscience-focused clinical stage company Neurovance reported positive results from the Phase IIA pilot study of its non-stimulant drug for ADHD, EB-1020 SR, in adult male patients with all ADHD sub...

Neurovance reports positive results from EB-1020 SR phase 2a pilot study in adult ADHD patients

Neurovance, Inc. today announced complete results from its phase 2a pilot study of EB-1020 SR, a non-stimulant, in adult male patients with all subtypes of ADHD (attention deficit hyperactivity disord...

Neurovance Completes Enrollment in Human Abuse Liability Study for Centanafadine (Formerly Called EB-1020) for Adult ADHD

—Study Intended to Confirm Reduced Potential for Abuse and Diversion— Neurovance, Inc. today announced that it has completed enrollment in a human abuse liability (...

Neurovance Appoints Brigitte Robertson, MD, Vice President, Clinical Development

—Dr. Robertson Brings ADHD Expertise to Advance Neurovance’s Centanafadine SR Program— —Neurovance’s Lead Product EB-1020 SR Granted Non-Proprietary Name...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Neurovance Inc.

Neurovance is a neuroscience-focused, clinical-stage biopharmaceutical company that specializes in triple reuptake inhibitors specifically optimized for adult attention deficit hy...

Neurovance, Inc.

Neurovance has been spun out of Euthymics Bioscience, Inc. to advance EB-1020, a norepinephrine and dopamine-preferring reuptake inhibitor for ADHD. In addition to EB-1020, Neurov...

More Information about "Neurovance, Inc." on BioPortfolio

We have published hundreds of Neurovance, Inc. news stories on BioPortfolio along with dozens of Neurovance, Inc. Clinical Trials and PubMed Articles about Neurovance, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Neurovance, Inc. Companies in our database. You can also find out about relevant Neurovance, Inc. Drugs and Medications on this site too.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Top five promising drugs Phase II (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE II TRIALS Drug Disease Company Sel-G1 Sickle cell anemia Selexys Pharmaceuticals NSI-566 Amyotrophic lateral sclerosis ...

Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record